Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study
1997

Chemoimmunotherapy for Metastatic Melanoma

Sample size: 43 publication Evidence: moderate

Author Information

Author(s): CJA Punt, CML van Herpen, RLH Jansen, G Vreugdenhil, EW Muller, PHM de Mulder

Primary Institution: University Hospital Nijmegen

Hypothesis

Can the combination of BOLD and interferon alpha improve response rates in patients with metastatic melanoma?

Conclusion

The study confirms that BOLD plus interferon alpha has activity in metastatic melanoma, but the response rate is lower than previously reported.

Supporting Evidence

  • The overall response rate was 27% with one complete and ten partial remissions.
  • Median overall survival was 5 months.
  • 81% of patients had visceral metastases.

Takeaway

This study tested a combination treatment for melanoma and found that it works, but not as well as earlier studies suggested.

Methodology

Patients were treated with a combination of chemotherapy and interferon alpha, and their responses were evaluated after treatment.

Potential Biases

The study population had worse prognostic factors compared to previous studies, which may affect the results.

Limitations

The response rate was lower than in previous studies, likely due to differences in patient selection.

Participant Demographics

The median age of participants was 58 years, with 27 men and 16 women, all having stage IV melanoma.

Statistical Information

Confidence Interval

95% CI 14-43%

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication